GlassScriptPhysician profile
Ellen J Gustafson
NPI 1245296896
$3,190.52
in general payments reported to CMS, 2019-2025
36 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.41 · 2020: $23.24 · 2021: $319 · 2022: $244 · 2023: $265 · 2024: $464 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.40 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,511.08 | 2021-2025 | |
| Celgene Corporation | $179.69 | 2022-2025 | Reblozyl |
| Daiichi Sankyo INC. | $150.74 | 2023-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $129.39 | 2021-2024 | Opdivo, Eliquis |
| Global Blood Therapeutics, INC. | $128.70 | 2020-2022 | |
| Pfizer INC. | $121.70 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $93.47 | 2021-2025 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $87.15 | 2021-2023 | Imbruvica |
| Taiho Oncology, INC. | $54.13 | 2024-2025 | |
| Cardinal Health 414 LLC | $52.65 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.03 | 2025 | Iclusig, Ninlaro |
| Lilly USA, LLC | $44.00 | 2019-2021 | |
| Abbvie INC. | $43.38 | 2025 | |
| Cti Biopharma Corp. | $43.22 | 2022-2023 | Vonjo |
| Astrazeneca Pharmaceuticals LP | $43.18 | 2021-2025 | Imfinzi, Enhertu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40.38 | 2021-2024 | Erleada |
| Eisai INC. | $38.75 | 2023-2024 | |
| Array Biopharma INC | $32.05 | 2025 | Mektovi, Lorbrena, Braftovi |
| Genentech USA, INC. | $29.04 | 2024 | Phesgo, Perjeta, Kadcyla |
| Alexion Pharmaceuticals, INC. | $26.16 | 2024 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $24.75 | 2024 | Monoferric |
| Recordati_rare_diseases_inc. | $24.23 | 2023 | Sylvant |
| Tempus Ai, INC | $23.23 | 2024 | |
| Alnylam Pharmaceuticals INC. | $22.49 | 2023 | Givlaari |
| Genzyme Corporation | $20.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.19 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.67 | 2022 | |
| Aadi Bioscience, INC. | $17.55 | 2023 | Fyarro |
| Incyte Corporation | $16.59 | 2025 | Jakafi |
| Acrotech Biopharma INC. | $16.16 | 2021 | |
| Verity Pharmaceuticals INC. | $15.98 | 2023 | Trelstar |
| Coherus Oncology, INC. | $15.72 | 2025 | Loqtorzi |
| Kite Pharma, INC. | $15.62 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.65 | 2021 | |
| Tesaro, INC. | $12.01 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.